[Phenibut potentiation of the therapeutic action of antiparkinson agents]

Zh Nevropatol Psikhiatr Im S S Korsakova. 1986;86(8):1146-8.
[Article in Russian]


It was observed in experiments on mice that the central action of phenibut (beta-phenyl-gamma-aminobutyric acid) diminished after destruction of brain dopaminergic neurons by 6-hydroxydopamine and after pretreatment with the dopamine receptor blocker haloperidol which suggests the dopaminergic component in the action of phenibut. In 13 of 16 patients receiving long-term treatment with antiparkinsonic drugs, addition of phenibut (0.25 g thrice daily for 10 days) resulted in marked clinical improvement with a significant increase of motor activity, as well as diminution of both rigidity and tremor. Follow-up showed a significant lowering of muscle tone of rigid muscles, augmentation of their strength and amplitude of movements. In 8 patients receiving phenibut without antiparkinsonic drugs the results were negligible.

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / administration & dosage*
  • Basal Ganglia Diseases / drug therapy*
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Muscle Rigidity / drug therapy
  • gamma-Aminobutyric Acid / administration & dosage
  • gamma-Aminobutyric Acid / analogs & derivatives*


  • Antiparkinson Agents
  • gamma-Aminobutyric Acid
  • 4-amino-3-phenylbutyric acid